SCHEMBL224957

SCHEMBL224957

ClCCN1CCCCCC1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.55
MAPT P10636 3/20 0.44
ALDH1A1 P00352 2/20 0.44
POLB P06746 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.42
CARM1 Q86X55 1/20 0.42
PRMT6 Q96LA8 1/20 0.42
PRMT8 Q9NR22 1/20 0.42
CYP1A2 P05177 2/20 0.41
LMNA P02545 1/20 0.41
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MBTD1 Q05BQ5 1/20 0.39
L3MBTL3 Q96JM7 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
TSHR P16473 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9966933 1.00 HRH3 (0.55) HRH3MAPTALDH1A1POLBL3MBTL1
SCHEMBL15462867 1.00 HRH3 (0.55) HRH3MAPTALDH1A1POLBL3MBTL1
SCHEMBL8023825 1.00
SCHEMBL19173238 1.00 HRH3 (0.55) HRH3MAPTALDH1A1POLBL3MBTL1
SCHEMBL11712553 1.00 HRH3 (0.55) HRH3MAPTALDH1A1POLBL3MBTL1
SCHEMBL12811 1.00
Hydrochloric Acid SCHEMBL9592 0.97 HRH3 (0.52) HRH3MAPTALDH1A1POLBL3MBTL1
Hydrochloric Acid SCHEMBL227556 0.97 HRH3 (0.52) HRH3MAPTALDH1A1POLBL3MBTL1
SCHEMBL263561 0.97
Hypochlorous Acid SCHEMBL10439976 0.94 HRH3 (0.50) HRH3MAPTALDH1A1POLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4392411-A1 PROCESS FOR THE PREPARATION OF CHLOROALKYL SUBSTITUTED CYCLIC AMINES Hovione Farmaciencia SA (PT) 2024-07-03 EP claimed
CN-118159526-A Process for preparing chloroalkyl substituted cyclic amines 好利安药理股份公司 2024-06-07 CN claimed
WO-2023030667-A1 PROCESS FOR THE PREPARATION OF CHLOROALKYL SUBSTITUTED CYCLIC AMINES HOVIONE SCIENTIA (IE) 2023-03-09 WO claimed
CN-104693144-B A kind of N-(2-chloroethyl) synthetic method of hexamethylene imine hydrochlorate 山东川成医药股份有限公司 2016-08-24 CN claimed
US-20240383854-A1 PROCESS FOR THE PREPARATION OF CHLOROALKYL SUBSTITUTED CYCLIC AMINES HOVIONE FARMACIENCIA SA (PT) 2024-11-21 US disclosed
EP-4392411-A1 PROCESS FOR THE PREPARATION OF CHLOROALKYL SUBSTITUTED CYCLIC AMINES Hovione Farmaciencia SA (PT) 2024-07-03 EP disclosed
CN-118159526-A Process for preparing chloroalkyl substituted cyclic amines 好利安药理股份公司 2024-06-07 CN disclosed
US-20240067639-A1 SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS University of Florida Research Foundation, Incorporation (US) 2024-02-29 US disclosed
US-20240067639-A1 SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS University of Florida Research Foundation, Incorporation (US) 2024-02-29 US disclosed
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2023-12-19 US disclosed
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2023-12-19 US disclosed
EP-4210703-A1 SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS Expansion Therapeutics, Inc. (US) 2023-07-19 EP disclosed
US-4133814-A ANTITUMOR AGENTS ELI LILLY AND COMPANY (US) 1979-01-09 US disclosed
US-4107205-A α-Aryl-α,α-bis[ω-(disubstituted amino)alkyl]acetamides and related compounds G. D. SEARLE & CO. (US) 1978-08-15 US disclosed
US-4104380-A Dibenzyl glycolic acid derivatives WARNER-LAMBERT COMPANY (US) 1978-08-01 US disclosed
US-4076937-A Dibenzyl glycolic acid derivatives WARNER-LAMBERT COMPANY (US) 1978-02-28 US disclosed
US-4001229-A ALKANESULFONAMIDO TRIPHENYLETHYLENES MEAD JOHNSON & COMPANY (US) 1977-01-04 US disclosed
US-3962334-A Aminoalkyl ethers of 2,2'- and 3,3'-dihydroxybenzil AMERICAN HOME PRODUCTS CORPORATION (US) 1976-06-08 US disclosed
US-3960886-A Substituted N-arylanilines STERLING DRUG INC. (US) 1976-06-01 US disclosed
US-3935191-A Aminoalkyl ethers of 2,2'- and 3,3'-dihydroxybenzil AMERICAN HOME PRODUCTS CORPORATION (US) 1976-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067639-A1 SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS FUS, SNRPE, RRBP1 HRH3 1527/4885MAPT 349/4885ALDH1A1 4793/4885
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ADORA2A, ADORA1, ADORA3 HRH3 416/4885MAPT 3868/4885ALDH1A1 571/4885
US-20240383854-A1 PROCESS FOR THE PREPARATION OF CHLOROALKYL SUBSTITUTED CYCLIC AMINES ETFB, TOP2B, MGMT HRH3 1013/4885MAPT 4023/4885ALDH1A1 1381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.